Cost Sharing

• 

  Subject Areas on Research

  • A Touchy Subject: Can Physicians Improve Value by Discussing Costs and Clinical Benefits With Patients? 
  • ACA Marketplace premiums and competition among hospitals and physician practices. 
  • Association of a P2Y12 Inhibitor Copayment Reduction Intervention With Persistence and Adherence With Other Secondary Prevention Medications: A Post Hoc Analysis of the ARTEMIS Cluster-Randomized Clinical Trial. 
  • Clinician-patient E-mail communication: challenges for reimbursement. 
  • Continental Divide? The attitudes of US and Canadian oncologists on the costs, cost-effectiveness, and health policies associated with new cancer drugs. 
  • Copayment Reduction Voucher Utilization and Associations With Medication Persistence and Clinical Outcomes: Findings From the ARTEMIS Trial. 
  • Copayment reductions generate greater medication adherence in targeted patients. 
  • Cost-sharing requirements and access to mental health care among medicare enrollees with schizophrenia. 
  • Effect of Medication Co-payment Vouchers on P2Y12 Inhibitor Use and Major Adverse Cardiovascular Events Among Patients With Myocardial Infarction: The ARTEMIS Randomized Clinical Trial. 
  • Effect of switching to a high-deductible health plan on use of chronic medications. 
  • Employee demand for health insurance and employer health plan choices. 
  • Experiences of health care costs among people with employer-sponsored insurance and bipolar disorder. 
  • Factors associated with enrollment, satisfaction, and sustainability of the New Cooperative Medical Scheme program in six study areas in rural Beijing. 
  • From physician to consumer: the effectiveness of strategies to manage health care utilization. 
  • How Should We Intervene on the Financial Toxicity of Cancer Care? One Shot, Four Perspectives. 
  • How price responsive is the demand for specialty care? 
  • Increasing copayments and adherence to diabetes, hypertension, and hyperlipidemic medications. 
  • Low-socioeconomic-status enrollees in high-deductible plans reduced high-severity emergency care. 
  • Overcoming barriers to discussing out-of-pocket costs with patients. 
  • Patient Financial Assistance Programs: A Path to Affordability or a Barrier to Accessible Cancer Care? 
  • Patient adherence to generic versus brand statin therapy after acute myocardial infarction: Insights from the Can Rapid Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the American College of Cardiology/American Heart Association Guidelines Registry. 
  • Payments, promotion, and the purple pill 
  • Pricing and Welfare in Health Plan Choice. 
  • Rationale and design of the Affordability and Real-world Antiplatelet Treatment Effectiveness after Myocardial Infarction Study (ARTEMIS): A multicenter, cluster-randomized trial of P2Y12 receptor inhibitor copayment reduction after myocardial infarction. 
  • Reduced Cost-sharing for Preventive Drugs Preferentially Benefits Low-income Patients With Diabetes in High Deductible Health Plans With Health Savings Accounts. 
  • Relationship between occurrence of surgical complications and hospital finances. 
  • Rural health prepayment schemes in China: towards a more active role for government. 
  • The Effect of Cost Sharing on an Employee Weight Loss Program: A Randomized Trial. 
  • The Parity Paradigm: Can Legislation Help Reduce the Cost Burden of Oral Anticancer Medications? 
  • The differential effect of compensation structures on the likelihood that firms accept new patients by insurance type. 
  • The effect of heavy drinking on social security old-age and survivors insurance contributions and benefits. 
  • The relationship between insurance coverage and psychiatric disorder in predicting use of mental health services. 
  • User fees for health services. Norwegian perspective on copayments. 
  • Value-based insurance design program in north Carolina increased medication adherence but was not cost neutral. 
  • Value-based insurance design: quality improvement but no cost savings. 
  • Value-based insurance design: the authors reply.